Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 22.14% is 670% above its 5-year average of 2.87%, near the high end of its 5-year range (0.32%–22.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 163.21% above its 12-month average of 8.41%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 22.14%.
DEBT TO ASSETS RATIO
22.14%
DEBT TO ASSETS RATIO AVG TTM
8.41%
DEBT TO ASSETS RATIO AVG 3Y
3.98%
DEBT TO ASSETS RATIO AVG 5Y
2.87%
DEBT TO ASSETS RATIO AVG 10Y
9.56%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+163.21%
CURRENT VS 3Y AVG
+455.55%
CURRENT VS 5Y AVG
+670.38%
CURRENT VS 10Y AVG
+131.60%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+24495.30%
vs the sector median at left
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Debt to Assets Ratio
22.14%
TTM Avg
8.41%
3Y Avg
3.98%
5Y Avg
2.87%
Market Cap
$2.06B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
Debt to Assets Ratio
0.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | 22.14% | 8.41% | 3.98% | 2.87% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | 0.01% | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.08B | 0.91% | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 0.18% | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 0.04% | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 0.73% | N/A | N/A | N/A |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 0.01% | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | 0.78% | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 0.08% | N/A | N/A | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 0.14% | N/A | N/A | N/A |
Debt/Assets
22.1%
Debt/Equity
0.37
Current Ratio
16.95
Interest Coverage
-73.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 22.14% |
| 2026-03-31 | 6.49% |
| 2025-12-31 | 5.64% |
| 2025-09-30 | 4.13% |
| 2025-06-30 | 3.66% |
| 2025-03-31 | 3.21% |
| 2024-12-31 | 2.84% |
| 2024-09-30 | 2.74% |
| 2024-06-30 | 3.58% |
| 2024-03-31 | 3.34% |
| 2023-12-31 | 4.29% |
| 2023-09-30 | 6.33% |
| 2023-06-30 | 1.57% |
| 2023-03-31 | 1.37% |
| 2022-12-31 | 1.21% |
| 2022-09-30 | 1.18% |
| 2022-06-30 | 3.04% |
| 2022-03-31 | 0.32% |
| 2021-12-31 | 0.51% |
| 2021-09-30 | 0.69% |
| 2021-06-30 | 1.34% |
| 2021-03-31 | 0.32% |
| 2020-12-31 | 0.35% |
| 2020-09-30 | 28.14% |
| 2020-06-30 | 27.46% |
| 2020-03-31 | 19.65% |
| 2019-12-31 | 27.44% |
| 2019-09-30 | 23.78% |
| 2019-06-30 | 20.81% |
| 2019-03-31 | 18.91% |
| 2018-12-31 | 15.57% |
| 2018-09-30 | 13.33% |
| 2018-06-30 | 12.35% |
| 2018-03-31 | 11.52% |
| 2017-12-31 | 18.91% |
| 2017-09-30 | 7.17% |
| 2017-06-30 | 7.70% |
| 2017-03-31 | 7.48% |
| 2016-12-31 | 24.54% |
| 2016-09-30 | 14.65% |
| 2016-06-30 | 12.22% |
| 2016-03-31 | 10.24% |
| 2015-12-31 | 8.56% |
| 2015-09-30 | 7.47% |
| 2015-06-30 | 8.44% |
| 2015-03-31 | 6.72% |
| 2014-12-31 | 0.99% |
| 2014-09-30 | 0.11% |
| 2014-06-30 | 0.10% |
| 2014-03-31 | 28.85% |
| 2013-12-31 | 18.98% |
